Emanuel Raschi - Concepedia

Author

Emanuel Raschi

Also Known As

Chiara Reno, E R Raschi, E Raschi, E. Raschi, Emanuel Raschi, Emanuel Raschi (487410), RASCHI, Emanuel, Raschi E, Raschi, E., Raschi, Emanuel

269

Publications

6.9K

Citations

H-Index

113

Concepts

All Affiliations

University of Bologna University of Verona IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola Azienda USL di Bologna Inserm

About

Emanuel Raschi is an author at University of Bologna specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	23	911
2	Public Health	7	7	172
3	Health Sciences	3	3	175
4	Management	1	1	13
5	Nursing	1	1	23

Emanuel Raschi

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration Michele Fusaroli, Francesco Salvo, Bernard Bégaud, Drug Safety	2024	213
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement Michele Fusaroli, Francesco Salvo, Bernard Bégaud, Drug Safety	2024	142
Drug‐induced <i>torsades de pointes</i>: data mining of the public version of the FDA Adverse Event Reporting System (AERS) Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, Pharmacoepidemiology and Drug Safety	2009	139
Antimicrobials and the Risk of Torsades de Pointes Elisabetta Poluzzi, Emanuel Raschi, Domenico Motola, Drug Safety Antimicrobial SusceptibilityHealth SciencesAntibioticsMedicineAntimicrobial Chemotherapy	2010	121
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database Emanuel Raschi, Carlo Piccinni, Elisabetta Poluzzi, Acta Diabetologica Metabolic SyndromeDiabetes ManagementHealth PolicyInsulin ManagementDiabetes	2011	120
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System Chiara Gastaldon, Emanuel Raschi, John M. Kane, Psychotherapy and Psychosomatics	2020	119
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment Emanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, Breast Cancer Research and Treatment	2020	103
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Targeted Oncology Drug SafetyDisproportionality AnalysisImmunotoxicologyAdverse EventMedicine	2019	95
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System Riccardo Mei, Emanuel Raschi, Emanuele Forcesi, International Journal of Cardiology VaccinationVaccine SafetyVaccine TargetImmunologyAutoimmunity	2018	86
Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system Emanuel Raschi, Elisabetta Poluzzi, Ariola Koci, British Journal of Clinical Pharmacology	2015	82

Page 1